How many institutions held PVLA - PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value in Q2 2025?

64 institutional investors reported PVLA - PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value for Q2 2025. Use the holders table for investor-level position and value details.

PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value (PVLA)

Q: What does CUSIP 697947109 represent in this 13F holders report?

CUSIP 697947109 is the security identifier for PVLA - PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value used to aggregate holder disclosures.

CUSIP: 697947109

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class: Equity / Common Stock, $0.01 par value
Shares outstanding: 11,842,870
Total 13F shares: 5,909,706
Share change: +781,679
Total reported value: $133,205,244
Price per share: $22.54
Number of holders: 64
Value change: +$16,635,084
Number of buys: 43
Number of sells: 11

Quarterly Holders Quick Answers

What is CUSIP 697947109?
CUSIP 697947109 identifies PVLA - PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2025
Previous quarter: Q1 2025

Recent filing periods for CUSIP 697947109:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024

Top shareholders of PVLA - PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Kaupinen Wes	13D/G	—	15%	1,644,869	$38,555,729	$0	13 Dec 2024	13D/G
SUVRETTA CAPITAL MANAGEMENT, LLC	13F	Company	6%	714,463	$19,997,819	—	31 Mar 2025	13F
BVF INC/IL	13F	Company	5.9%	696,555	$19,496,574	—	31 Mar 2025	13F
Frazier Life Sciences Management, L.P.	13F	Company	5.8%	690,012	$19,313,436	—	31 Mar 2025	13F
Samsara BioCapital, LLC	13F	Company	5.7%	679,486	$19,018,813	—	31 Mar 2025	13F
ADAMS STREET PARTNERS LLC	13F	Company	3.5%	409,666	$11,466,551	—	31 Mar 2025	13F
Samsara BioCapital, L.P.	13D/G	—	3.1%	339,743	$8,989,600	-$8,989,600	30 Jun 2025	13D/G
MILLENNIUM MANAGEMENT LLC	13F	Company	2.3%	269,837	$7,552,738	—	31 Mar 2025	13F
Nantahala Capital Management, LLC	13F	Company	2.1%	250,062	$6,999,235	—	31 Mar 2025	13F
Woodline Partners LP	13F	Company	1.6%	194,167	$5,434,734	—	31 Mar 2025	13F
Opaleye Management Inc.	13F	Company	1.5%	172,357	$4,824,272	—	31 Mar 2025	13F
Blue Owl Capital Holdings LP	13F	Company	1.2%	140,259	$3,925,849	—	31 Mar 2025	13F
VANGUARD GROUP INC	13F	Company	1.2%	138,433	$3,874,740	—	31 Mar 2025	13F
Dellora Investments LP	13D/G 3/4/5	no longer 10% owner	1.3%	141,079	$3,306,892	$0	13 Dec 2024	13D/G 3/4/5
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.97%	114,388	$3,201,720	—	31 Mar 2025	13F
BlackRock, Inc.	13F	Company	0.94%	110,758	$3,100,116	—	31 Mar 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.8%	94,199	$2,638,116	—	31 Mar 2025	13F
ADAR1 Capital Management, LLC	3/4/5	10%+ Owner	— class O/S missing	144,641	$2,297,246	—	09 Aug 2024	3/4/5
ROYCE & ASSOCIATES LP	13F	Company	0.6%	71,514	$2,001,677	—	31 Mar 2025	13F
AWM Investment Company, Inc.	13F	Company	0.59%	69,416	$1,942,954	—	31 Mar 2025	13F
Todd C. Davis	3/4/5	Director	— mixed-class rows	149,597 mixed-class rows	$1,787,516	—	10 Jun 2025	3/4/5
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	13F	Company	0.41%	48,664	$1,362,105	—	31 Mar 2025	13F
DAFNA Capital Management LLC	13F	Company	0.37%	43,348	$1,213,311	—	31 Mar 2025	13F
MARSHALL WACE, LLP	13F	Company	0.26%	30,345	$849,356	—	31 Mar 2025	13F
Strid Group, LLC	13F	Company	0.25%	29,219	$817,840	—	31 Mar 2025	13F
BVF PARTNERS L P/IL	3/4/5	Other*	— mixed-class rows	39,919 mixed-class rows	$618,794	—	13 Dec 2024	3/4/5
Cresset Asset Management, LLC	13F	Company	0.18%	20,911	$585,299	—	31 Mar 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.16%	19,053	$533,293	—	31 Mar 2025	13F
TORONTO DOMINION BANK	13F	Company	0.16%	18,872	$528,227	—	31 Mar 2025	13F
NORTHERN TRUST CORP	13F	Company	0.14%	16,635	$465,614	—	31 Mar 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.13%	15,258	$427,071	—	31 Mar 2025	13F
DELTEC ASSET MANAGEMENT LLC	13F	Company	0.11%	12,500	$349,875	—	31 Mar 2025	13F
STATE STREET CORP	13F	Company	0.1%	12,062	$337,615	—	31 Mar 2025	13F
UBS Group AG	13F	Company	0.08%	10,054	$281,411	—	31 Mar 2025	13F
MORGAN STANLEY	13F	Company	0.08%	9,907	$277,297	—	31 Mar 2025	13F
BALYASNY ASSET MANAGEMENT L.P.	13F	Company	0.07%	8,176	$228,846	—	31 Mar 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.06%	7,609	$212,976	—	31 Mar 2025	13F
Spire Wealth Management	13F	Company	0.02%	2,516	$70,423	—	31 Mar 2025	13F
CITIGROUP INC	13F	Company	0.02%	2,246	$62,866	—	31 Mar 2025	13F
GROUP ONE TRADING LLC	13F	Company	0%	312	$8,733	—	31 Mar 2025	13F
Tim Demuth	3/4/5	Chief Medical Officer	— class O/S missing	6,000	$5,100	—	13 May 2022	3/4/5
BARCLAYS PLC	13F	Company	0%	63	$1,763	—	31 Mar 2025	13F
WELLS FARGO & COMPANY/MN	13F	Company	0%	50	$1,400	—	31 Mar 2025	13F
Truvestments Capital LLC	13F	Company	0%	14	$392	—	31 Mar 2025	13F
Allworth Financial LP	13F	Company	0%	5	$128	—	31 Mar 2025	13F
JONES FINANCIAL COMPANIES LLLP	13F	Company	0%	3	$84	—	31 Mar 2025	13F
JPMORGAN CHASE & CO	13F	Company	0%	3	$84	—	31 Mar 2025	13F
Stephen S. Yoder	3/4/5	Chief Executive Officer, Director	— class O/S missing	634,021	—	—	24 Feb 2023	3/4/5
Ahmed Mousa	3/4/5	Chief Business Officer	— class O/S missing	249,080	—	—	24 Feb 2023	3/4/5
Hitto Kaufmann	3/4/5	Chief Scientific Officer	— class O/S missing	249,080	—	—	24 Feb 2023	3/4/5

Institutional Holders of PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value (PVLA) as of Q2 2025

As of 30 Jun 2025, PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value (PVLA) was held by 64 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 5,909,706 shares. The largest 10 holders included Frazier Life Sciences Management, L.P., SUVRETTA CAPITAL MANAGEMENT, LLC, BVF INC/IL, Woodline Partners LP, BlackRock, Inc., SAMSARA BIOCAPITAL, LLC, MILLENNIUM MANAGEMENT LLC, ADAMS STREET PARTNERS LLC, Nantahala Capital Management, LLC, and GEODE CAPITAL MANAGEMENT, LLC. This page lists 64 institutional shareholders reporting positions in this security for the Q2 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders

Q2 2025 holders

Holder diff

Investor	Q1 2025 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q1 2025 Value $	Q2 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.